ClinicalTrials.gg
CompletedNCT05856227Updated Jul 28, 2025Results posted

Late-onset Sepsis in Term and Pre-term Neonates and Infants up to 3 Months of Age

A Phase 3 interventional study of Ceftobiprole medocaril in Neonatal Sepsis, sponsored by Basilea Pharmaceutica. Completed at 14 sites in 8 countries. Open to participants aged 3 Days to 3 Months. Per ClinicalTrials.gov, last updated 2025-07-28.

Sponsored by Basilea Pharmaceutica · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
9
Allocation
Not applicable
Ages
3 Days to 3 Months
Sex
All
01

Study summary

This study evaluated the safety, pharmacokinetics and efficacy of ceftobiprole in term and pre-term newborn babies and infants up to 3 months of age with late-onset sepsis (LOS). Ceftobiprole is an antibiotic which belongs to a group of medicines called 'cephalosporin antibiotics'. It is approved for its use to treat adults and children with pneumonia in many European and non-European countries.

Read the detailed description

This was a multicenter, open-label, single-arm, multiple-dose study of intravenous (IV) ceftobiprole medocaril (prodrug of the active moiety ceftobiprole). It could be combined with ampicillin and/or an aminoglycoside based on the Investigator's judgement according to manufacturer's instructions and/or local standard of care.

Following screening, ceftobiprole was administered as a 2-hour infusion at a dose of 7.5 mg/kg every 12 hours to 15 mg/kg every 8 hours, depending on age and weight.

The target treatment duration was 3-10 days, which could be extended to 14 days if considered clinically necessary by the Investigator.

02

Conditions studied

  • Neonatal Sepsis

Browse trials for

Keywords

  • Late-onset sepsis
  • Neonates
  • Infants
03

In context

Neonatal Sepsis

193 studies on the registry are indexed under Neonatal Sepsis; 42 are open to participants now.

This study's enrollment of 9 is below the median of 182 across 103 interventional studies indexed under Neonatal Sepsis.

Browse Neonatal Sepsis studies →

Lead sponsor

Basilea Pharmaceutica is the lead sponsor of 60 studies on the registry; 7 are open to participants now.

Of its 22 completed or terminated interventional studies of FDA-regulated products, 15 (68%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
3 Days to 3 Months
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • from parent(s) or other legally acceptable representative (LAR) to participate in the study
  • Male or female, with a gestational age of ≥ 24 weeks and a post-natal age ranging from ≥ 3 days to ≤ 3 months
  • Diagnosis of documented or presumed bacterial LOS requiring administration of systemic antibiotic treatment
  • Sufficient vascular access to receive study drug and to allow blood sampling at a site separate from the study drug infusion line

Key Exclusion Criteria:

  • septic shock not responding to 60 minutes of vasopressor treatment within 48 hours before enrollment
  • Proven ventilator-associated pneumonia
  • Proven central nervous system infection (e.g., meningitis, brain abscess)
  • Proven osteomyelitis, infective endocarditis, or necrotizing enterocolitis
  • Impaired renal function or known significant renal disease, as evidenced by an estimated (using the Schwartz formula or other applicable formula) calculated to be less than 2/3 of normal for the applicable age group, OR urinary output \< 0.5 mL/kg/h (measured over at least 8 hours), OR requirement for dialysis
  • Progressively fatal underlying disease, or \< 30 days
  • Use of systemic antibacterial therapy for longer than 72 hours within 7 days before start of study medication
  • Participation in another clinical study with an product within 30 days of enrollment in the current study
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
9 participants (actual)

Study arms

  • Experimental
    Treatment Arm: Ceftobiprole

    Ceftobiprole medocaril: 7.5 mg/kg to 15 mg/kg

    Drug: Ceftobiprole medocaril

Interventions

  • Ceftobiprole medocaril: 7.5 mg/kg every 12 hours to 15 mg/kg every 8 hours, administered IV as a 2-hour infusion.

06

What researchers measure

Primary outcomes

  1. Number of Patients With Adverse Events (AEs)

    Number of patients with AEs, serious adverse events (SAEs), AEs leading to discontinuations and AEs of special interest

    Time frame: Up to 5-7 weeks

Secondary outcomes

  1. Maximum Observed Plasma Concentration (Cmax) of Ceftobiprole, Ceftobiprole Medocaril, and Open-ring Metabolite

    Observed pharmacokinetic parameter Cmax of ceftobiprole (the active moiety), its pro-drug ceftobiprole medocaril and the open-ring metabolite in term and pre-term neonates with post-natal age up to 3 months

    Time frame: On treatment Day 3 prior to and 2, 4, and 8 hours after the start of the first ceftobiprole infusion of the day

  2. Number of Patients With a Clinical Response

    Clinical cure rate at the end of treatment (EOT) at day 3-14 and test of cure (TOC) at 7-14 days after last ceftobiprole dose visits in the Intent-to-Treat (ITT) population

    Time frame: Up to 28 days

  3. Number of Participants With Improved Signs and Symptoms of Late Onset Sepsis (LOS)

    Improved signs and symptoms of LOS (including fever, hypothermia, abnormal heart rate, signs of impaired circulation, petechial rash or sclerema neonatorum, respiratory distress, gastrointestinal distress, irritability, lethargy and/or muscular or arterial hypotonia) assessed at Day 3, EOT, and TOC visits (ITT) populations.

    Time frame: Up to 28 days

  4. Number of Patients With a Microbiological Response

    Microbiological eradication or presumed eradication rate at the EOT and TOC visits.

    Time frame: Up to 28 days

07

Results

Posted Jul 28, 2025

Participant flow

Treatment was administered in hospital setting

Participant flow — Overall Study
MilestonePre-term NeonatesTerm Neonates
Started63
Completed42
Not completed21
Withdrew: Adverse event01
Withdrew: Due to investigator absence10
Withdrew: Cerebrospinal fluid test positive for s. aureus10

Outcome measures

PrimaryNumber of Patients With Adverse Events (AEs)

Number of patients with AEs, serious adverse events (SAEs), AEs leading to discontinuations and AEs of special interest

Time frame:
Up to 5-7 weeks
Reported as:
Count of participants · Participants
Number of Patients With Adverse Events (AEs)
ParticipantsPre-term NeonatesTerm Neonates
Any AE33
Study-drug-related AE00
SAE11
Study-drug-related SAE00
AE leading to treatment discontinuation01
AE of special interest11
SecondaryMaximum Observed Plasma Concentration (Cmax) of Ceftobiprole, Ceftobiprole Medocaril, and Open-ring Metabolite

Observed pharmacokinetic parameter Cmax of ceftobiprole (the active moiety), its pro-drug ceftobiprole medocaril and the open-ring metabolite in term and pre-term neonates with post-natal age up to 3 months

Time frame:
On treatment Day 3 prior to and 2, 4, and 8 hours after the start of the first ceftobiprole infusion of the day
Reported as:
Median · μg/mL
Maximum Observed Plasma Concentration (Cmax) of Ceftobiprole, Ceftobiprole Medocaril, and Open-ring Metabolite
μg/mLPre-term NeonatesTerm Neonates
Ceftobiprole17.2 (11.0 to 22.6)28.4 (19.1 to 33.8)
Ceftobiprole medocaril0.585 (0.276 to 5.70)0.552 (0.376 to 2.59)
Open-ring metabolite1.18 (0.624 to 1.69)1.68 (0.998 to 2.06)
SecondaryNumber of Patients With a Clinical Response

Clinical cure rate at the end of treatment (EOT) at day 3-14 and test of cure (TOC) at 7-14 days after last ceftobiprole dose visits in the Intent-to-Treat (ITT) population

Time frame:
Up to 28 days
Reported as:
Count of participants · Participants
Number of Patients With a Clinical Response
ParticipantsPre-term NeonatesTerm Neonates
EoT — Cure42
EoT — Failure01
EoT — Unevaluable20
TOC — Cure42
TOC — Failure01
TOC — Unevaluable20
SecondaryNumber of Participants With Improved Signs and Symptoms of Late Onset Sepsis (LOS)

Improved signs and symptoms of LOS (including fever, hypothermia, abnormal heart rate, signs of impaired circulation, petechial rash or sclerema neonatorum, respiratory distress, gastrointestinal distress, irritability, lethargy and/or muscular or arterial hypotonia) assessed at Day 3, EOT, and TOC visits (ITT) populations.

Time frame:
Up to 28 days
Reported as:
Count of participants · Participants
Number of Participants With Improved Signs and Symptoms of Late Onset Sepsis (LOS)
ParticipantsPre-term NeonatesTerm Neonates
Day 3 — Resolved11
Day 3 — Improved10
Day 3 — Unchanged31
Day 3 — Worsened01
Day 3 — Not done10
EOT — Resolved11
EOT — Improved10
EOT — Unchanged21
EOT — Worsened10
EOT — Not done11
TOC — Resolved22
TOC — Improved20
TOC — Unchanged10
TOC — Worsened11
TOC — Not done00
SecondaryNumber of Patients With a Microbiological Response

Microbiological eradication or presumed eradication rate at the EOT and TOC visits.

Time frame:
Up to 28 days
Reported as:
Count of participants · Participants
Number of Patients With a Microbiological Response
ParticipantsPre-term NeonatesTerm Neonates
EOT — Eradication41
EOT — Presumed eradication01
EOT — Persistence01
EOT — Unevaluable20
TOC — Eradication41
TOC — Presumed eradication01
TOC — Persistence01
TOC — Unevaluable20

Adverse events

Collected over Up to 5-7 weeks. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Pre-term Neonates0/6 (0%)1/6 (16.7%)3/6 (50%)
Term Neonates0/3 (0%)1/3 (33.3%)3/3 (100%)
Most frequent serious events
Most frequent serious events
EventPre-term NeonatesTerm Neonates
ThrombocytopeniaBlood and lymphatic system disorders0/61/3
Respiratory failureRespiratory, thoracic and mediastinal disorders0/61/3
Enterobacter sepsisInfections and infestations0/61/3
Intestinal obstructionGastrointestinal disorders1/60/3
Most frequent other events
Showing 10 of 12
Most frequent other events
EventPre-term NeonatesTerm Neonates
ThrombocytosisBlood and lymphatic system disorders0/61/3
Gastrointestinal haemorrhageGastrointestinal disorders0/61/3
Adrenal haemorrhageEndocrine disorders0/61/3
Vena cava thrombosisVascular disorders0/61/3
OedemaGeneral disorders2/60/3
Withdrawal syndromeGeneral disorders0/61/3
Intraventricular haemorrhage neonatalNervous system disorders1/60/3
Bronchopulmonary dysplasiaRespiratory, thoracic and mediastinal disorders1/60/3
HypoglycaemiaMetabolism and nutrition disorders1/60/3
HyponatraemiaMetabolism and nutrition disorders1/60/3

Baseline characteristics

Age, Continuous
Age, Continuous(Days)Pre-term NeonatesTerm NeonatesTotal
Mean19.2 ± 11.0526.7 ± 4.5121.7 ± 9.77
Sex: Female, Male
Sex: Female, Male(Participants)Pre-term NeonatesTerm NeonatesTotal
Female314
Male325
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Pre-term NeonatesTerm NeonatesTotal
Hispanic or Latino101
Not Hispanic or Latino538
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Pre-term NeonatesTerm NeonatesTotal
American Indian or Alaska Native000
Asian000
Native Hawaiian or Other Pacific Islander000
Black or African American000
White538
More than one race000
Unknown or Not Reported101
Region of Enrollment
Region of Enrollment(participants)Pre-term NeonatesTerm NeonatesTotal
United States202
Poland011
Bulgaria213
Lithuania011
Estonia202
Gestational age
Gestational age(Weeks)Pre-term NeonatesTerm NeonatesTotal
Mean28.5 ± 4.6839.0 ± 1.7332.0 ± 6.48
Baseline weight
Baseline weight(gram)Pre-term NeonatesTerm NeonatesTotal
Mean1429.2 ± 777.493156.7 ± 1094.362005.0 ± 1193.01
08

Study locations

14 sites
  • NorthShore University HealthSystem-Evanston Hospital
    Evanston, Illinois 60201, United States
  • West Virginia University
    Morgantown, West Virginia 26506, United States
  • MHAT Dr. Stamen Iliev AD Montana, Neonatology Department
    Montana, 3400, Bulgaria
  • UMHAT "Sveti Georgi" EAD, Pediatric surgery Clinic
    Plovdiv, 4000, Bulgaria
  • "Acibadem City Clinic University Hospital Tokuda" EAD, Neonatology Department
    Sofia, 1407, Bulgaria
  • Tallinn Childrens' Hospital
    Tallinn, 13419, Estonia
  • Klinikum der Universität München, Kinderklinik und Kinderpoliklinik im Dr. von Haunerschen Kinderspital
    Munich, Bavaria 80337, Germany
  • Pauls Stradins Clinical University Hospital
    Riga, 1002, Latvia
  • Children Clinical University Hospital - Neonatology Clinic
    Riga, 1004, Latvia
  • Lithuanian Health Science University Hospital Kauno klinikos - Neonatology Clinic
    Kaunas, 50161, Lithuania
  • Vilnius University Hospital Santaros klinikos - Neonatology Center
    Vilnius, 08410, Lithuania
  • Ginekologiczno-Położniczy Szpital Kliniczny im. Marcinkowskiego
    Poznan, 60-535, Poland
  • Szpital Uniwersytecki - Klinika Neonatologii
    Wroclaw, 50-556, Poland
  • Univerzitna nemocnica Martin
    Martin, 03659, Slovakia
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Aug 2023 to primary completion in Dec 2024, 16 months.

Results were first posted in Jul 2025, 7 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 17, 2023
First posted
May 12, 2023
StartActual
Aug 6, 2023
Primary completionActual
Dec 18, 2024
CompletionActual
Dec 18, 2024
Results first posted
Jul 28, 2025
Last update
Jul 28, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 28, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05856227
Responsible party
Sponsor
First posted
May 12, 2023
Start date
Aug 6, 2023
Primary completion
Dec 18, 2024
Completion
Dec 18, 2024
Results posted
Jul 28, 2025
Last update
Jul 28, 2025

Study contacts

Marc Engelhardt, MD
study director · Basilea Pharmaceutica International Ltd, Allschwil

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ceftobiprole medocaril

Start the discussion